Clinical Trial

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open label, non-randomized, 2-stage phase II, single arm study to determine the efficacy of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide vaccine as a priming mechanism to prevent anti-PD1 resistance in patients with platinum-refractory stage III/IV ovarian cancer (OC).
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2022-07-26; most recent amendment 2026-03-12.
Status change: Recruiting → Not Yet Recruiting 2024-11-27
Status change: Suspended → Recruiting 2024-09-04
Status change: Recruiting → Suspended 2024-01-16
Status change: Not Yet Recruiting → Recruiting 2023-08-24
Trial Details
NCT Number NCT05479045
Lead Sponsor Georgetown University
Collaborators: Coherus Oncology, Inc.
Conditions Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3
Enrollment 24 participants
Start Date 2026-09
Primary Completion 2027-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-16